aldosterone
Small moleculeexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2006 (NCT00700479)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetSupplementation
supplementation
Chemistry & pharmacology
Loading structure…
SMILES
C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12- Mol. weight
- 360.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL273453 ↗
Also known as
- 11beta,21-dihydroxy-3,20-diketo-4-pregnen-18-al
- 11beta,21-dihydroxy-3,20-diketo-4-pregnen-18-al
- 11beta,21-dihydroxy-3,20-diketopregn-4-ene-18-al
- 11beta,21-dihydroxy-3,20-diketopregn-4-ene-18-al
- 11beta,21-dihydroxy-3,20-dioxo-4-pregnen-18-al
- 11beta,21-dihydroxy-3,20-dioxo-4-pregnen-18-al
- 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al
- 11beta,21-dihydroxy-3,20-dioxopregn-4-en-18-al
- 11beta,21-dihydroxy-3,20-dioxo-pregn-4-ene-18-al
- 11beta,21-dihydroxy-3,20-dioxo-pregn-4-ene-18-al
- 11beta,21-dihydroxypregn-4-ene-3,18,20-trione
- 11beta,21-dihydroxypregn-4-ene-3,18,20-trione
- 18-aldocorticosterone
- 18-aldocorticosterone
- 18-formyl-11beta,21-dihydroxy-4-pregnene-3,20-dione
- 18-formyl-11beta,21-dihydroxy-4-pregnene-3,20-dione
- 18-oxocorticosterone
- 18-oxocorticosterone
- aldocorten
- aldocorten
- aldocorten
- aldocortene
- aldocortene
- aldocortene
- aldocortin
- aldocortin
- aldocortin
- aldosterona
- aldosterona
- aldosterone
- aldosterone
- aldosterone
- aldosterone
- aldosterone
- aldosterone
- aldosterone
- aldosterone
- (+)-aldosterone
- (+)-aldosterone
- aldosteronum
- aldosteronum
- d-aldosterone
- d-aldosterone
- electrocortin
- electrocortin
- electrocortin
- elektrocortin
- elektrocortin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05640128 | N/A | Jan 2, 2018 | University of Caen-Normandie |
| NCT03029806 | N/A | Jan 2, 2017 | Harvard University |
| NCT00732160 | N/A | Sep 1, 2008 | National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Vanderbilt University |
| NCT00700479 | Phase 1 | Jan 1, 2006 | Pfizer, Yale University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2008 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2008 |
| Pfizer | For profit | 1 | 0 | 1 | 2006 |
| University of Caen-Normandie | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2006 |
7 organizations
Page 1 / 1